AstraZeneca PLC ("AstraZeneca") today provided notice of the voluntary withdrawal from listing on The Nasdaq Stock Market LLC ("Nasdaq") of (i) its American Depositary Shares (the "ADSs"), representing AstraZeneca's ordinary shares of $0.25 each (the "Ordinary Shares") on a two-for-one basis and (ii) debt securities issued by AstraZeneca or its wholly-owned subsidiary AstraZeneca Finance LLC and guaranteed by AstraZeneca (the "Debt Securities"). As previously announced on 29 September 2025, AstraZeneca plans to complete a direct listing of its Ordinary Shares and the Debt Securities on the New York Stock Exchange (the "NYSE"), which will be effective after market close on 30 January 2026. The direct listing is a part of AstraZeneca's shareholder approved plan to harmonise its share listing structure to deliver a global listing for global investors in a global company. Following implementation of the Harmonised Listing Structure, shareholders will be able to trade their interests in the Ordinary Shares across the London Stock Exchange, Nasdaq Stockholm and the NYSE.
The listing of the ADSs and the Debt Securities on Nasdaq is expected to cease on 30 January 2026 and the Ordinary Shares and Debt Securities are expected to commence trading on the NYSE from Monday, 2 February 2026. The Ordinary Shares will continue to be listed under the ticker symbol "AZN".
Debt securities
For details on the Debt Securities, including outstanding US dollar-denominated and US-listed debt securities please visit https://www.astrazeneca.com/investor-relations/debt-investors.html
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide.
